The mixed dopaminc (DA) agonist/antagonist tcrguridc acts as a I)A antagonist on normosensitivc receptors but shows DA agonistic properties at supersensitive DA receptors. Such a compound could offer an alternative to the treatment of Parkinson's disease with indirect or direct DA agonists. The present study compares the actions of terguride, 4-12 mg/kg i.p., in naive common marmoscts with its effects in animals rendered parkinsonian by administration of 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridinc (MPTP), 2 months or 10 months previously, in order to test its antiparkinsonian efficacy. Tcrguride reduced locomotor activity in naive common marmosets, similar to its effects in rodents and in line with the DA antagonistic activity of the compound. In marmosets treated with MPTP 2 months previously and exhibiting pronounced bchavioural motor deficits, terguride stimulated locomotor activity, showing DA agonistic properties under these conditions. In contrast, the locomotor activity of animals that had recovered from MPTP treatment 10 months previously was not altered by terguride. It is concluded that terguridc has anti-akinetic efficacy in this primate model of Parkinson's disease. In addition, terguride offers a unique opportunity to differentiate, pharmacologically, the extent of dopaminergic recovery from MPTP treatment in this primate species.
I. Introduction
The current treatment of Parkinson's disease with indirect or direct dopamine (DA) agonists (i.e., L-Dopa, lisuride, pergolide or bromocriptinc) is limited by side effects. Whereas somc initial adverse reactions such as nausea and vomiting usually disappear due to rapid tolerance, the incidence of others such as fluctuations in motor performance and involuntary movements increases after long-term treatment with L-Dopa (Marsden and Parkcs, 1976) . Psychosis is another limiting side effect of all dopaminergic therapies, especially in elderly patients. A balanced stimulation of DA receptc.rs, taking into account the differential status of DA receptor sensitivity in the course of the disease, could lead to a more specific therapeutic effect and reduction of side effects. Mixed DA agonists/antagonists, with terguridc being the prototype compound, are promising for such an approach. Tcrguride, a derivative of the dopaminergic ergolinc lisuride, binds with high affinity to rat striatal DA 1) 2 and to a lesser extent to DA D~ binding sites (Valchfir ct al., 1987) . The compound acts as a DA antagonist in normal rats but shows DA agonistic properties in reserpine-treated rodents (Wachtcl and Dorow, 1983) . In naive rats, terguride dose dependently inhibits locomotor activity. However, stimulation occurs after subchronic prctreatment with reserpine. Similarly, terguride does not induce stereotypies in rats treated acutely with reserpine, but does so after subchronic treatment with reserpine (Wachtel ct al., 1984) . Furthermore, and in common with classical DA agonists, terguridc suppresses hyperprolactinaemia in female rats pretreated with reserpine and induces contralateral rotations in rats injected unilaterally with 6-hydroxydopaminc into the substantia nigra (Dlab~c and Krej(:i, 1980; lJSschmann et al., 1991a) .
Administration of 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) to man or non-human primates (Davis et al., 1979; Langston et al., 1983; Burns et al., 1983) including common marmosets (Jenner ct al., 19841 induccs a parkinsonian syndromc duc to the selective destruction of nigrostriatal neurones, which causes a substantial decrease in the DA content of the caudate nucleus and putamen and a corresponding decrease in [~H]DA uptake (Jenner el al., 1984) . The deficits in motor performance produced by MPTP trcatmcnt of common marmosets respond to classical anti-parkinsonian drugs such as L-Dopa in combination with a peripheral decarboxylase inhibitor (Jenner et al., 1984) , or DA rcccptor agonists such as (+)-PHNO (Nomoto et al., 19871, N-0437 (l.6schmann ct al., 1989) or the ergoline derivative lisuridc (L6sch-mann ct al., 1991b). The MPTP-treated monkey appears to be the most suitable pharmacological model of Parkinson's disease currently available.
Common marmosets recover from the initial symptoms induced by MPTP treatment over a period of several months. This bchavioural recovery, is associated with increased DA turnover in the caudatc-putamcn (Jenner et al., 1984; Rose ct al., 19891 and is not reverscd by further treatment with MPTP (Ueki et al., 19891 . The present study was designed to test the hypothesis that the behavioural recovery in common marmosets after MPTP treatment would be associated with a change in their behavioural response to a mixcd DA agonist/antagonist. Wc therefore compared the actions of terguride in naive common marmosets to its effects in groups of animals exposed to MPTP either 2 months or 10 months prior to the administration of terguride. The results obtained under these conditions are discussed in view of the pharmacological effects of tcrguride in patients.
Materials and methods

Animals
Common marmosets (Callithrix jacchus) of either sex weighing 280-420 g and aged 6-10 years at the beginning of the study were used. The animals were housed in pairs or alone under standard conditions at a temperature of 27°C (+ I°C) and 50% relative humidity with a 12-h light-dark cycle (light on from 6:00 to 18:00 h). The animals had free access to food pellets (Mazuri primate diet) and tap water, and in addition received a daily ration of fresh fruit and Mazuri marmoset jelly. During MPTP treatment and throughout the following weeks the animals were hand-fed with Mazuri marmoset jelly and fresh fruit puree until they were able to maintain themselves. Electrolyte, nutrient and fluid balance were maintained by s.c. infusion of an electrolyte, amino acid and vitamin solution (Duphalyte, Duphar, UK) when necessary.
Measurement of locomotor actit:ity
Ix)comotor activity was measured simultaneously in four aluminium cages (50 × 60 × 70 cm) with stainless steel grid doors (50 × 70 cm) identical to thc animals' home cages but equipped with eight horizontally orientated sets of infrared photocells. Across the cage three beams wcrc located at floor level and one along each of the two pcrchcs. Other beams were directed from front-to-back of the cage at floor level and abc~ve each pcrch. The number of light beam interruptions due to the animal's movements were accumulated in 10-min intervals and recorded for 360 rain, using a Commodore CBM 4032 computer. The animals were allowed to acclimatize to the test cage for a minimum of 30 rain prior to drug treatment.
Behat:ioural obsercations
In parallcl to the automated recording of locomotor activity the animals were observed under blinded conditions through a one-way mirror. Motor behaviour was rated qualitatively to determine the presence or absence of stereotypy, head twitches, wet-dog shakes or grooming, oral movements, co-ordination of movement (good/impaired) and other obvious motor signs in 5-min intervals for 360 rain after drug administration. The maximal score for each item was 72.
Drugs and solutions
The following compounds were used: MPTP (lmethyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride; Schering AG) and tcrguride (Sobering AG). MPTP was dissolved in sterile physiological saline and tcrguridc was suspended in sterile physiological saline containing 10(I g/1 polycthoxylated castor oil (Cremophor EL, BASF, FRG). All solutions were prepared immediately before administration.
MPTP treatment
The animals were treated with MPTP in doses of 2 mg/kg s.c. daily for up to 6 days. Since the response of individual animals differed markedly, variable dose regimes were applied to obtain comparable initial motor deficits. Impairment of motor function was quantified daily with a rating scale (L/ischmann ctal., 1989). The animals were treated until they reached a maximal disability score of 18 24 h after the last MPTP injection. The cumulative doses administered ranged from 8 to 12 mg/kg. After MPTP treatment the animals recovered from acute effects over a period of some weeks. During the following months a further gradual recovery, from the MPTP effects was obscrvcd. One group of three animals was tested 2 months (group A) aad a second group of thrcc animals 10 months (group B) after exposure to MPTP.
Drug treatments
A group of four marmosets was treated with vehicle aad one of the three doses of tcrguridc (4.0, 8.0 or 12.0 mg/kg i.p.) ovcr the following weeks, allowing 1 week recovery between experiments. Treatments wcrc rand~mizcd within the group. MPTP-trcatcd marmosets were tested either 2 months (group A, N = 3) or 10 months (group B, N = 3) after MPTP treatment with vehicle or one of the three doses of tcrguride (4.0, 8.0 or 12.0 mg/kg i.p.) in a identical design. All experiments started at 11:00 a.m. and finished at 5:00 p.m.
Z Data analysis
The means _+ S.E.M. wcrc calculated for time courses and accumulated locomotor counts of the different treatment groups. Statistical differences were calculated for accumulated locomotor counts by the non-parametric Page test for non-independent data. lntraindividual monotone trends of treatment effects were detected using the ordered alternative: vehicle < 4.0 < 8.0 < 12 mg/kg, using exact distributions followed by sequential tests against two alternative hypotheses (vehicle < 4.0 < 8.0 mg/kg) or (vehicle < 4.0 and 8.0 < 12.(I mg/kg) when appropriate.
Results
When adapted to the environment of the test cages, naive common marmosets showed very little locomotor activity when not disturbed. Injection of vehicle was followed by a 30-min period of exploratory activity but, 1 and 4) . At later times vehicle-treated animals were more active whereas terguride-treated animals showed almost complete akinesia. Prior to behavioural testing, all animals of group A (treatment with MPTP 2 months before the experiment) showed a reduction in basal locomotor activity and exhibited slower and less coordinated movements, reduced checking movements of the head and eyeblinks as well as abnormal postures of some parts of the body. The behavioural deficits were different in group B (treatment with MPTP 10 months before testing). Locomotor activity was still reduced in one of these animals whereas another showed signs of hyperexcitability and unrest. The behaviour of the third animal was not different from that of controls.
Animals treated with MPTP 2 months prior to the experiment (group A) showed reduced locomotor activity when exposed to vehicle. Terguridc stimulated locomotor activity in the first I80 min after administration. Because stereotyped movements were elicited by the higher doses tested, 4.0 mg/kg of tcrguride was most effective ( fig. 4 and table 1 ). The stimulatory effect of tcrguride was more pronounced during the last 3 h of Ilowcvcr, due to the variability of iudividual animal responses, this effect was not statistically significant. In common marmosets exposed to MPTP 10 months prior to the experiment, terguridc had no effect upon locomotor activity.
all doses tested, although the effect did not seem to be dose-dependent. During the second 3-h period, terguride showed a tendency to stimulate locomotor activity. Again, this effect was not significant (figs. 3 and 5) for the 6-h observation period. None of the doses of terguride tested induced pronounced stereotyped movements in this group of animals (table 1).
Discussion
In rodents without lesions, terguride has DA antagonistic properties, resulting in a reduction of locomotor activity and in catalepsy when higher doses are administered. In line with these findings, the compound reduces exploratory locomotor activity of normal common marmosets. This depressant effect Iasts up to 6 h. DA agonistic properties arc unmasked in rodents pretreated subchronically with reserpine (Wachtel et al., 1984) . It is likely that the depletion of monoaminergic terminals may lead to an increased sensitivity of postsynaptic receptors. The anti-parkinsonian activity of terguride in the MPTP-treated primate, the most reliablc model fl)r Parkinson's disease at present available, has been shown previously. The compound induces rotations in monkeys rendered hcmiparkinsonian by intracarotid infusion of MPTP (Brihckc et al., 1988) . In accord with these findings, our data indicate that DA agonistic effects in the MPTP-trcatcd common marmoset arc also critically dependent on the receptor status. A clear stimulatory effect was only seen in animals treated 2 months previously with MPTP when they had not recovered bchaviourally from the MlrfP treatment. In the first 3 h, 4 mg/kg of terguride produced the greatest response ( fig. 4 ) whereas in the 6-h period 4 and 8 mg/kg stimulated locomotor activil.y ( fig. 5 ). In animals that had recovered from MPTP treatment given 10 months previously, tcrguride inhibi,.cd locomotor activity in the first 3 h, as it did in formal marmosets, although this effect was not statistically significant, llowever, in the 6-h period, all doses tested slightly stimulated locomotor activity, a response consistent with the weak DA agonistic effects of tcrguride under these conditions. We hypothesize that the bchavioural recovery of common marmosets is accompanied by a normalization of receptor sensitivity duc to changes in either the binding affinity or the coupling of receptors to second messenger systems. Thus, in aniraals recovered from prior MPTP treatment, the increased I)A turnover ) could lead to a higher availability of DA and subsequent normalization of the sensitivity of presynaptic autoreceptors. Under these conditions tcrguride would act as autoreceptor agonist, resulting in a reduced I)A release and inhibition of locomotor activity during the initial 3-h period. In the second 3-h period, tcrguridc would exert weak DA agonistic properties at postsynaptic receptors.
An alternative explanation involves the partial DA agonistic properties of terguride. Thus, the increased DA turnover could lead to a higher availability of DA, with terguride antagonizing the effects of endogenous I)A. The initial inhibition of locomotor activity could be explained by such a phenomenon. Since terguridc did not reduce but slightly increased locomotor activity in recovered common marmosets over the 6-h period, the latter hypothesis seems less likely.
Two faccts of the effects of tcrguridc arc of interest when compared with the effects of direct DA agonists such as (+)- PHNO (Nomoto et al., 1987) in this animal raodcl. First, tcrguridc did not cause a rapid and sustained locomotor hyperactivity even with the relatively high doses used. Second, the normal diurnal pattern of locomotor activity was preserved. Increased activity after treatment with terguride was seen during periods of higher basal locomotor activity nnder control conditions. Both observations contrast with the stimulatory effect on locomotor activity seen in reserpinizcd-rodents and are compatible with the idea that terguride 'enables' voluntary locomotion in the MPTP-treated marmoset rather than causes hyperstimulation. This atypical pharmacological profile, in which DA agonistic and DA antagonistic properties arc combined in one molecule, has been described as mixed DA agonism/antagonism in rodents. Our data show similar effects of terguride in a primate species.
The unique pharmacological profile of terguridc suggests an interesting range of possible indications, some of which have already been tested in clinical trials. Like classical DA agonists, single doses of tcrguride ranging from 0.25 to 1.0 mg lower prolactin 251 levels in humans and produce endocrine effects identical to those seen with bromocriptinc, but with less side effects. In a double-blind cross-over study, subjects could not distinguish the lower tcrguridc doses from placebo and 1 mg of tcrguridc was always preferred to 2.5 mg bromocriptinc (Ciccarclli et al., 1988) . Clinical observations confirm that terguride is useful in the treatment of hyperprolactinaemic conditions including prolactinomas (Dallabonzana et al., 1986) . Antiparkinsonian effects have been reported when terguride was used as monotherapy or combined with L-Dopa in advanced disease (Corsini et al., 1985) . In open clinical trials in paticnts with Parkinson's disease, especially in elderly patients (Briicke et al., 1986) , there was a low frequency of typical dopamincrgic side effects such as nausea, cmcsis or orthostatic hypotension. However, in a double-blind study in dc now) patients terguride was better tolerated but less active than lisuride after 3 months of therapy and its possible long-term effects are still trader investigation (U.K. Rinnc, personal communication). In placebo-controlled double-blind studies in patients with motor fluctuations, terguridc added to L-Dopa had a significant effect on disability and also improved wearing off and dyskinesias (E. Martignoni and G. Nappi, personal communication). In these studies antidyskinetic and anti-akinctic effects of terguridc wcrc obse~'ed in the same patients. Tcrguridc had very pronounced anti-dyskinetic effects without interference with the anti-akinctic effects of L-Dopa in parkinsonian patients with motor fluctuations as shown in a double-blind placebo-controlled study (Baronti et al., 1989 and submitted for publication). Tcrguridc has positive effects on tardive dyskincsia even in the presence of ncurolcptic drugs (Silk6 ct al., 1987) . Finally, in an open clinical trial, including 11 patients with chronic schizophrenia and marked negative symptoms, tcrguride improved symptomatology in eight patients on the scale for assessment of negative symptoms (SANS). In none of the patients were psychotic symptoms elicited and the compound was well tolerated (Olbrich and Schanz, 1988) .
Mixed DA agonist/antagonists may have good antiparkinsonian actions with fewer side effects, especially in patients susceptible to motor fluctuations, dyskinesias, psychosis or enhanced sensitivity towards dopamincrgic drugs.
In conclusion, the MPTP-treated common marmoset offers a useful pharmacological model and is of predictive value for the characterization of not only classical direct DA agonists but also mixed DA agonist/antagonists. Tcrguride can be used in a pharmacological in vivo test for the assessment of the sensitivity status of central DA receptors in MPTP-trcated primates. Tcrguride could also be valuable for the assessment of the function of dopaminergic cell transplants.
